LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Начало・Списък с акции・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Затворен

СекторЗдравеопазване

21.03 1.2

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.65

Максимум

21.32

Ключови измерители
By Trading Economics
Приходи	-29M -11M
Продажби	-24M 105M
EPS	-0.09
Марж на печалбата	-10.717
Служители	354
EBITDA	-31M -8.5M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+66.01% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-329M 2.6B
Предишно отваряне	19.83
Предишно затваряне	21.03

Настроения в новините

By Acuity

46%

54%

140 / 344 Класиране в Healthcare

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

26.05.2026 г., 16:52 ч. UTC

Значими събития в новините

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26.05.2026 г., 23:57 ч. UTC

Печалби

Sociedad Quimica 1Q Rev $1.76B >SQM

26.05.2026 г., 23:57 ч. UTC

Печалби

Sociedad Quimica 1Q EPS $1.28 >SQM

26.05.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26.05.2026 г., 21:54 ч. UTC

Печалби

Webco Industries 3Q EPS $11.61 >WEBC

26.05.2026 г., 21:54 ч. UTC

Печалби

Webco Industries 3Q Sales $179.6M >WEBC

26.05.2026 г., 21:48 ч. UTC

Пазарно говорене

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26.05.2026 г., 21:00 ч. UTC

Пазарно говорене

ESG Roundup: Market Talk

26.05.2026 г., 20:58 ч. UTC

Придобивния, сливания и поглъщания

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

26.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

26.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

26.05.2026 г., 19:22 ч. UTC

Пазарно говорене

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26.05.2026 г., 19:17 ч. UTC

Пазарно говорене

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26.05.2026 г., 18:56 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26.05.2026 г., 18:03 ч. UTC

Пазарно говорене

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26.05.2026 г., 17:42 ч. UTC

Пазарно говорене

Grains Await Fresh Trading Catalyst -- Market Talk

26.05.2026 г., 17:33 ч. UTC

Пазарно говорене

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26.05.2026 г., 17:21 ч. UTC

Пазарно говорене

Canada Faces a Labor Market Squeeze -- Market Talk

26.05.2026 г., 16:52 ч. UTC

Пазарно говорене

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26.05.2026 г., 16:43 ч. UTC

Пазарно говорене

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26.05.2026 г., 16:24 ч. UTC

Пазарно говорене

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26.05.2026 г., 16:21 ч. UTC

Пазарно говорене

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

26.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

26.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

26.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Auto & Transport Roundup: Market Talk

26.05.2026 г., 16:16 ч. UTC

Пазарно говорене

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26.05.2026 г., 16:01 ч. UTC

Пазарно говорене

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26.05.2026 г., 15:21 ч. UTC

Пазарно говорене

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

66.01% нагоре

12-месечна прогноза

Среден 34.63 USD 66.01%

Висок 36 USD

Нисък 33 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Arcutis Biotherapeutics Inc през последните 3 месеца.

Настроение

By Acuity

140 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.